[
  {
    "ts": null,
    "headline": "Vertex Presents New Data on the Benefits of ALYFTREK",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pooled research found that sweat chloride (SwCl) levels […]",
    "url": "https://finnhub.io/api/news?id=69d7a2ff00f3c7eb90a45354c0a20ec6df064fa3715c3864a7be841a6e37d09b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749684917,
      "headline": "Vertex Presents New Data on the Benefits of ALYFTREK",
      "id": 135196880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pooled research found that sweat chloride (SwCl) levels […]",
      "url": "https://finnhub.io/api/news?id=69d7a2ff00f3c7eb90a45354c0a20ec6df064fa3715c3864a7be841a6e37d09b"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Early-Stage Research Updates Show Promise",
    "summary": "Crispr Therapeutics: Early-Stage Research Updates Show Promise",
    "url": "https://finnhub.io/api/news?id=caae6e7b3b1f6be99caa7c74810b32480ed9664e867755e3e4f0a9c2aaa33a47",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749633699,
      "headline": "Crispr Therapeutics: Early-Stage Research Updates Show Promise",
      "id": 135179569,
      "image": "",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=caae6e7b3b1f6be99caa7c74810b32480ed9664e867755e3e4f0a9c2aaa33a47"
    }
  },
  {
    "ts": null,
    "headline": "Tracking RenTech's 13F Portfolio - Q1 2025 Update",
    "summary": "RenTechâs Q1 2025 13F portfolio value decreased slightly to $66.07B. Check out the significant stake increases and major reductions in the portfolio.",
    "url": "https://finnhub.io/api/news?id=052b117f799eed2c573d9cf928e9f7d274bca070d09deafdfe5c1b0b7e7e4a08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749604283,
      "headline": "Tracking RenTech's 13F Portfolio - Q1 2025 Update",
      "id": 135173822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153363652/image_2153363652.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "RenTechâs Q1 2025 13F portfolio value decreased slightly to $66.07B. Check out the significant stake increases and major reductions in the portfolio.",
      "url": "https://finnhub.io/api/news?id=052b117f799eed2c573d9cf928e9f7d274bca070d09deafdfe5c1b0b7e7e4a08"
    }
  }
]